Stockreport

Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity [Yahoo! Finance]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF 54% of participants on the 24 mg dose achieved resolution of obesity (BMI CT-388 demonstrated a safety and tolerability profile generally consistent with its drug cl [Read more]